Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Appointment of joint corporate brokers

9 May 2022 13:00 BST Appointment of joint corporate brokers AstraZeneca PLC announced that its joint corporate brokers will be Morgan Stanley & Co. International plc and J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove), effective as of 9 May 2022. AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal &

Mandatory notification of trade – Shares for employees 2022

Employees in more than 20 countries have been offered the opportunity to buy Orkla shares at a discount, for the amount of NOK 10 000, NOK 15 000 or NOK 30 000 (included the discount). The purchase price will be set at Orkla's closing price on 13 May 2022, minus 15% discount.The offer is valid from 9 – 13 May 2022. This programme was introduced in 1999. Please see the attachment for an overview of the primary insiders who have ordered shares in Orkla on 9 May 2022. The purchase price and the number of shares acquired by the primary insiders, as well as their updated shareholdings,

Corem initiates repurchase of own shares

In accordance with a decision at the Annual General Meeting on 27 April 2022, Corem Property Group AB (publ) will initiate a buyback program of its own shares. Purchase of own shares may take place on one or more occasions during the period until the next Annual General Meeting.At the Annual General Meeting the Board was authorized, until the next Annual General Meeting, to decide on acquiring the company’s own shares. Acquisitions may take place of at most the number of shares so that after each acquisition the group’s total holding of its own shares amounts to at most ten per cent of

Scientific article about the advantageous S2-based protein secretion system ExpreS2 and a moderate-throughput research variant called FAS2FURIOUS

Hørsholm, Denmark, May 9, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Frontiers in Bioengineering and Biotechnology published an article about the ability of S2 cells to express challenging targets.Excerpts: “…FAS2FURIOUS is comparable in effort to simple E. coli systems and allows users to clone and test up to 46 constructs in just 2 weeks. Given the ability of S2 cells to express challenging targets, including receptor ectodomains, secreted glycoproteins, and viral antigens, FAS2FURIOUS represents an attractive orthogonal

Power production in April 22.9 GWh

Weaker winds than normal in April resulted in a power production of 22.9 GWh, compared to the month’s budget of 26.9 GWh. Halmstad, 9 May 2022 ARISE AB (publ) For further information, please contact: Per-Erik Eriksson, CEO Arise AB, +46 702 409 902 This information is information that Arise AB is obliged to make public pursuant to the EU MarketAbuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 13.05 CEST on 9 May, 2022. Regarding information about how we process your personal data we refer to our

Recent study from Japan confirms the value of original GastroPanel® biomarkers diagnosis of autoimmune atrophic gastritis.

Biohit Oyj press release  9.5.2022 at 14.00 local time (EEST)   The publisher of the topmost medical journal Nature (1) reported recently a study that evaluated the accuracy of serological testing for the biomarkers (pepsinogens and gastrin) in diagnosis of autoimmune atrophic gastritis (AAG) (1). This cross-sectional study provides results that are similar as recently reported by Biohit partners in a population-based screening setting, where GastroPanel® showed unrivalled test characteristics in non-invasive screening of asymptomatic healthy people for AAG (2).     AAG is

Invitation to presentation of Movinn’s report for Q1 2022

Company Announcement nr. 13 - 2022Press Release9 May 2022 13.00 (CEST)  Copenhagen, Denmark - Movinn A/S published its interim report for Q1 2022 on Thursday 5 May 2022 .On Tuesday 10 May there will be held two seperate web conferences.  Web Conference 1 w/ HC Andersen Capital at 12.30 CEST, the company will hold a web conference hosted by analyst and digital IR provier H.C. Andersen Capital with the attendance of CEO Patrick Blok. After the presentation there will be a Q&A session. The web conference will be held in English. You can join the conference by computer or

Nokian Tyres: Disclosure under chapter 9, section 10 of the securities market act

Nokian Tyres plc Stock Exchange Release May 9, 2022 at 1:40 p.m. Nokian Tyres has received an announcement from JPMorgan Chase & Co. on May 6, 2022, in accordance with the Finnish Securities Market Act Chapter 9, Section 5. According to the announcement, the indirect holding in Nokian Tyres shares owned by the funds and accounts managed by JPMorgan Chase & Co. fell below the level of 5% of the share capital in Nokian Tyres plc, as a result of share transactions concluded on May 4, 2022. The indirect shareholding of the funds and accounts managed by JPMorgan Chase & Co. in Nokian Tyres

Zalaris receives SAP Recognized Expertise 2022 for Talent Management

SAP has recognised Zalaris' exceptional expertise and extensive project experience with the SAP Recognized Expertise for Talent Management in Germany.To obtain the title of SAP Recognized Expertise, an SAP Partner must meet various demanding examination criteria. The award confirms that Zalaris' consultants are professionally trained and certified and have implemented a large number of successful projects in the field of talent management. This recognition also documents that customers rate Zalaris’ project performance positively. As a SAP Gold Partner, Zalaris offers a wide range of

Productive hotspot for the food industry

Anuga FoodTec in Cologne is the most important source of impetus for the international food and beverage industry. As the world's most important supplier fair, it covers all aspects of food production and after two years of pandemic, the hotspot was back in business the last week of April. Lesjöfors’ experts of metal conveyor belts for the food industry were there.The Dutch Lesjöfors company Tribelt that specializes in the manufacture of metal conveyor belts for the food industry, participated with a stand at the fair. We asked Henri Veldhuis, MD of Tribelt a couple of questions about the

Premix signs $79.9 million contract for a new production facility in the U.S.

The major agreement will help secure critical diagnostic supplies in the United States and better serve Premix’s global customers.     Gastonia / Helsinki, May 9, 2022 – The U.S. Department of Defense, working with the Department of Health and Human Services, awarded a $79.9 million contract to Premix, Inc. to establish a plastic compound manufacturing plant in North Carolina. The facility will primarily produce plastic materials for diagnostic testing. The facility will be built in Gaston County, centrally located in the growing region of advanced manufacturing in the southeast U.

Hexagon Purus Maritime receives inaugural order for hydrogen cylinders for maritime applications

Hexagon Purus Maritime, a wholly owned subsidiary of Hexagon Purus, has received its inaugural order for cylinders to be used in onboard storage of hydrogen in maritime vessels. Hexagon Purus’ type 4 hydrogen cylinders will be used in onboard swappable storage containers for maritime vessels operating in the inland waterways in Europe. The value of the order is approximately EUR 1.1 million (approx. NOK 11 million). Driving Energy Transformation “Our Type 4 high-pressure cylinders are at the core of what we do and with their corrosion resistance and long lifetime, the cylinders enable

Alligator Bioscience expands its Board of Directors with the appointment of Staffan Encrantz and Denise Goode

Lund, Sweden, May 9, 2022 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the appointment of Staffan Encrantz and Denise Goode as members of the company's Board of Directors. Mr. Encrantz is the founder and Chairman of Allegro Investment Fund, a $750 million fund which has been investing in companies across a number of industries for 30 years and is also a major shareholder in Alligator Bioscience. Ms. Goode has more than 25 years of experience in business leadership and innovation, having held a number of senior executive and board-level positions in the pharmaceutical and

ChemoTech supports a Ukrainian hospital by selling an IQwave™ at a discounted price

After ChemoTech recently received a direct request for help from Ulis Hospital in Ukraine, the Company of course agreed to sell an IQwave™ to the hospital at a heavily discounted price.The registration of ChemoTech's TSE system, also known as IQwave 3.0 CE, began in autumn 2021 in Ukraine. This process was completed just before Russia's invasion of the country began.   During the spring, the Company had ongoing contact with the distributor, who already had a complete launch strategy that had to be suspended due to the current war. Ulis Hospital played a central role in the distributor'

GET Group AB (publ) resolves upon an issue of units to professional investors

The board of directors in GET Group AB (publ) (‘GET Group’ or the ‘Company’) has today resolved, pursuant to the authorisation by the annual general meeting held on 30 June 2021, on an issue of 18,000,000 shares and 18,000,000 warrants to professional investors. The new shares and warrants shall be issued as a unit where one unit consists of one share and one warrant of series 2022:1. The subscription price for all units is in total SEK 927,829.50.The board of directors in GET Group has today resolved, pursuant to the authorisation by the annual general meeting held on 30 June 2021, on a

Pagero Group AB (publ) (“Pagero”) to make a recommended cash offer to acquire Tungsten Corporation plc (“Tungsten”)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY RESTRICTED JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. THIS PUBLICATION IS NEITHER AN OFFER TO BUY OR SELL NOR AN INVITATION TO TENDER OR OFFER TO BUY OR SELL SHARES.The boards of directors of Tungsten and Pagero are pleased to announce that they have agreed the terms of a recommended all cash offer to be made by Pagero to acquire the entire issued and to be issued ordinary share capital of Tungsten at a price of

Optomed Oyj - Managers' Transactions

Optomed Plc - Managers' Transactions – 9 May 2022, at 12.00 EET Optomed Oyj - Managers' Transactions ____________________________________________   Person subject to the notification requirement Name: Tauriainen, Reijo Position: Member of the Board/Deputy member Issuer: Optomed Oyj LEI: 7437009IVYWGEE4S7B77   Notification type: INITIAL NOTIFICATION Reference number: 7437009IVYWGEE4S7B77_20220509091406_5 ____________________________________________   Transaction date: 2022-05-06 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN:

Optomed Oyj - Managers' Transactions

Optomed Plc - Managers' Transactions – 9 May 2022, at 12.00 EET Optomed Oyj - Managers' Transactions ____________________________________________   Person subject to the notification requirement Name: Kopsala, Seppo Position: Chief Executive Officer Issuer: Optomed Oyj LEI: 7437009IVYWGEE4S7B77   Notification type: INITIAL NOTIFICATION Reference number: 7437009IVYWGEE4S7B77_20220509091134_4 ____________________________________________   Transaction date: 2022-05-06 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI4000410881

Optomed Oyj - Managers' Transactions

Optomed Plc - Managers' Transactions – 9 May 2022, at 12.00 EET Optomed Oyj - Managers' Transactions ____________________________________________   Person subject to the notification requirement Name: Mäkinen, Seppo Position: Member of the Board/Deputy member Issuer: Optomed Oyj LEI: 7437009IVYWGEE4S7B77   Notification type: INITIAL NOTIFICATION Reference number: 7437009IVYWGEE4S7B77_20220509091542_6 ____________________________________________   Transaction date: 2022-05-06 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN:

Cline presents at Aktiedagen Göteborg 16[th] May at 3pm

Cline Scientific AB (“Cline” or “The Company”) is participating in Aktiespararna’s Aktiedagen Göteborg at Svenska Mässan on Monday the 16th May 15:00 (in Swedish). CEO Patrik Sundh and VP of R&D Dr. Hanne Evenbratt will present Cline and answer your questions.Participants can also watch the live broadcast at www.aktiespararna.se/tv/live. The event is open to everyone and does not require any membership in Aktiespararna. No registration is required to follow the event digitally.   Participants can ask questions to the presenters by sending an SMS to 079-347 98 45 or emailing event@

Optomed Oyj - Managers' Transactions

Optomed Plc - Managers' Transactions – 9 May 2022, at 12.00 EET Optomed Oyj - Managers' Transactions ____________________________________________   Person subject to the notification requirement Name: Salonen, Petri Position: Member of the Board/Deputy member Issuer: Optomed Oyj LEI: 7437009IVYWGEE4S7B77   Notification type: INITIAL NOTIFICATION Reference number: 7437009IVYWGEE4S7B77_20220509091233_4 ____________________________________________   Transaction date: 2022-05-06 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN:

Tietoevry’s commitments to Science Based Targets verified

Tietoevry ’s carbon reduction targets have been verified by the Science Based Targets initiative  (SBTi) as being in line with the level of reduction needed to limit global warming to 1.5°C. This is an important milestone towards Tietoevry’s ambition of becoming net zero in own operations by 2025.To highlight the importance of sustainability across its operations, the company has included ESG indicators, CO\2\ reductions and diversity and inclusion, as part of its incentive program for the management. ”We take it upon ourselves to reduce our own carbon

REPORT ON MANAGERS’ TRANSACTIONS IN DAMPSKIBSSELSKABET NORDEN A/S

ANNOUNCEMENT NO. 113 - 9 MAY 2022 Under Article 19 of the Market Abuse Regulation Dampskibsselskabet NORDEN A/S is required to report transactions in Dampskibsselskabet NORDEN A/S’ shares by persons discharging managerial responsibilities and their close relatives. Name: Jan RindboReason: Reporting duty, CEOIssuer: Dampskibsselskabet NORDEN A/SISIN code: DK0010269844Instrument: SharesTransaction: Exercise of share optionsTrading date: 5 May

Flagging notification in accordance with Chapter 9 Section 10 of the Finnish Securities Markets Act

Basware Corporation, stock exchange release, 09 May 2022 at 11:30 a.m. EESTBasware Corporation has received on 6 May 2022 the following notification pursuant to Chapter 9, Section 5 of the Finnish Securities Market Act from The Goldman Sachs Group, Inc. according to which their total holding of shares of Basware Corporation has increased above five (5) percent on 5 May 2022. According to the notification, the reason for the notification was an acquisition or disposal of shares or voting rights and acquisition or disposal of financial instruments. Basware Corporation has one series of

There are no items matching the current filter
There are no more items matching the current filter
Back to top